Pediatric Rheumatology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Lupus. 2023 Nov;32(13):1548-1554. doi: 10.1177/09612033231211065. Epub 2023 Oct 25.
To report the differences in phenotypic characteristics, disease course, and outcome in monogenic and sporadic childhood lupus (SC-lupus) from a single tertiary childhood lupus clinic.
A descriptive, observational, cross-sectional study was conducted. Data were retrospectively collected at the last follow-up visit on patients with monogenic lupus proven by genetic variants and SC-lupus seen between June 1997 and July 2022. SC-lupus patients were selected by systematic sampling from lupus patients presenting to our lupus clinic; the first patient was chosen randomly, and the subsequent patients were chosen at intervals of three. Data comprised the clinical and laboratory findings, disease activity using the SLEDAI, and damage measured by the pSDI.
A total of 54 patients with a median disease duration of 6.8 (IQR 3.5-10.5) years were included. There were 27 patients with monogenic lupus and 27 patients with SC-lupus, with a median age at disease onset of 3.5 (IQR 1.0-6.0), and 9.5 (IQR 7.0-11.8), respectively. ( < 0.05). The rate of consanguinity and family history of lupus were higher in monogenic lupus patients. The two groups were comparable. However, monogenic lupus patients showed more gastrointestinal tract symptoms, and failure to thrive ( < 0.05). They also had more infections. The frequency of the autoantibody profile was higher in monogenic lupus patients. Belimumab was more frequently used in monogenic lupus while rituximab in SC-lupus patients. Monogenic lupus patients had a higher mean SLEDAI, but statistically, it was insignificant. Patients with monogenic lupus had greater disease damage, with a higher mean pSDI and a higher mortality rate ( < 0.05).
Patients with monogenic lupus are likely to have an early disease onset and a strong family history of lupus, as well as a guarded prognosis, which is likely due to the disease's severity and frequent infections. These differences may be related to the high consanguinity rate and underlying genetic variants.
报告单基因和散发性儿童狼疮(SC-狼疮)在单一三级儿童狼疮诊所中的表型特征、疾病过程和结局差异。
进行描述性、观察性、横断面研究。从 1997 年 6 月至 2022 年 7 月在我们的狼疮诊所就诊的单基因狼疮患者(通过遗传变异证实)和 SC-狼疮患者的最后一次随访中回顾性收集数据。SC-狼疮患者通过系统抽样从我们的狼疮诊所就诊的狼疮患者中选择;第一个患者是随机选择的,随后的患者每隔三个选择一个。数据包括临床和实验室发现、使用 SLEDAI 评估的疾病活动度以及使用 pSDI 测量的损伤。
共纳入 54 例患者,中位疾病病程为 6.8(IQR 3.5-10.5)年。27 例患者患有单基因狼疮,27 例患有 SC-狼疮,发病年龄中位数分别为 3.5(IQR 1.0-6.0)和 9.5(IQR 7.0-11.8)。(<0.05)。单基因狼疮患者的近亲结婚率和狼疮家族史更高。两组无差异。然而,单基因狼疮患者胃肠道症状和生长不良更常见(<0.05)。他们也有更多的感染。单基因狼疮患者的自身抗体谱频率更高。单基因狼疮患者更常使用贝利尤单抗,而 SC-狼疮患者更常使用利妥昔单抗。单基因狼疮患者的平均 SLEDAI 更高,但统计学上无显著性差异。单基因狼疮患者的疾病损伤更大,平均 pSDI 更高,死亡率更高(<0.05)。
单基因狼疮患者可能具有更早的发病年龄和狼疮的强烈家族史,以及预后不良,这可能与疾病的严重程度和频繁感染有关。这些差异可能与高近亲结婚率和潜在的遗传变异有关。